Cuorips Inc. (JP:4894)
:4894
Want to see JP:4894 full AI Analyst Report?
Top Page
Cuorips Inc.
(4894)
Select Model
Select Model
Rating:48Neutral
Price Target:
¥6,861.00
▲(10.13% Upside)
Action:ReiteratedDate:03/24/26
The score is primarily constrained by ongoing losses and heavy cash burn despite strong recent revenue growth and a debt-free, equity-heavy balance sheet. Technical signals are weak with the price below key moving averages and a negative MACD, while valuation support is limited by a negative P/E and no dividend yield data.
Positive Factors
Revenue Acceleration
A 404% YoY revenue increase demonstrates meaningful commercial traction and accelerating product adoption from a small base. Over a multi-month horizon this durable trend supports scalable revenue potential, improving the odds that fixed R&D and SG&A can be absorbed as sales grow.
Negative Factors
Large Operating Losses & Cash Burn
Persistently negative operating and free cash flow shows the business consumes substantial cash to run operations and pursue R&D. This structural cash burn raises dilution and financing risk over months, forcing dependence on external funding unless losses are reduced or new capital is secured.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Acceleration
A 404% YoY revenue increase demonstrates meaningful commercial traction and accelerating product adoption from a small base. Over a multi-month horizon this durable trend supports scalable revenue potential, improving the odds that fixed R&D and SG&A can be absorbed as sales grow.
Read all positive factors
Cuorips Inc. (4894) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥55.00B
Dividend YieldN/A
Average Volume (3M)107.56K
Price to Earnings (P/E)―
Beta (1Y)1.10
Revenue Growth922.89%
EPS Growth-0.53%
CountryJP
Employees59
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-30.15
Shares Outstanding8,273,376
10 Day Avg. Volume98,200
30 Day Avg. Volume107,556
Financial Highlights & Ratios
PEG Ratio16.56
Price to Book (P/B)12.03
Price to Sales (P/S)379.55
P/FCF Ratio-74.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Cuorips Inc. Business Overview & Revenue Model
Company Description
Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development...
Cuorips Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 260.31M | 175.21M | 23.10M | 38.28M | 13.91M | 220.00K |
| Gross Profit | 119.12M | 91.56M | -60.47M | -57.64M | -82.09M | -73.78M |
| EBITDA | -511.99M | -513.57M | -518.38M | -371.78M | -280.46M | -207.93M |
| Net Income | -652.25M | -644.34M | -632.18M | -452.08M | -375.34M | -307.83M |
Balance Sheet | ||||||
| Total Assets | 5.75B | 5.74B | 6.18B | 3.59B | 4.04B | 4.36B |
| Cash, Cash Equivalents and Short-Term Investments | 4.85B | 4.79B | 5.58B | 2.94B | 3.34B | 3.54B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 324.59M | 211.91M | 200.96M | 133.79M | 149.36M | 141.95M |
| Stockholders Equity | 5.42B | 5.53B | 5.98B | 3.45B | 3.90B | 4.22B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -892.81M | -474.83M | -412.18M | -249.45M | -950.97M |
| Operating Cash Flow | 0.00 | -812.62M | -451.06M | -401.61M | -220.76M | -282.80M |
| Investing Cash Flow | 0.00 | -117.99M | -33.50M | -8.97M | -28.44M | -670.21M |
| Financing Cash Flow | 0.00 | 143.11M | 3.12B | 10.69M | 48.54M | 3.77B |
Cuorips Inc. Technical Analysis
Negative
6230.00
Price Trends
7644.20
Negative
7203.20
Negative
6907.80
Positive
Market Momentum
-88.38
Negative
47.24
Neutral
54.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4894, the sentiment is Negative. The current price of 6230 is below the 20-day moving average (MA) of 7078.00, below the 50-day MA of 7644.20, and below the 200-day MA of 6907.80, indicating a neutral trend. The MACD of -88.38 indicates Negative momentum. The RSI at 47.24 is Neutral, neither overbought nor oversold. The STOCH value of 54.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4894.
Cuorips Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥16.36B | 120.78 | ― | ― | -7.33% | -167.46% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥21.52B | -34.16 | ― | ― | -7.24% | -201.01% | |
50 Neutral | ¥42.53B | -13.30 | ― | ― | -81.43% | 48.15% | |
49 Neutral | ¥10.46B | -8.14 | ― | ― | -56.71% | -23.09% | |
48 Neutral | ¥55.00B | -49.98 | ― | ― | 922.89% | -0.53% | |
45 Neutral | ¥18.80B | -11.30 | ― | ― | ― | 13.18% |
* Healthcare Sector Average
JP:4894
Cuorips Inc.
6,630.00
-310.00
-4.47%
JP:4593
Healios KK
333.00
10.00
3.10%
JP:4599
StemRIM Inc.
299.00
-18.00
-5.68%
JP:4978
ReproCELL Inc.
173.00
31.00
21.83%
JP:7774
Japan Tissue Engineering Co., Ltd.
553.00
-108.00
-16.34%
JP:7776
CellSeed Inc.
270.00
-281.00
-51.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.